- Home
- JXG vs ONCO Comparison
JXG vs ONCO Comparison
Compare JXG & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- ONCO
- Stock Information
- Founded
- JXG N/A
- ONCO 2018
- Country
- JXG China
- ONCO United States
- Employees
- JXG N/A
- ONCO N/A
- Industry
- JXG
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- ONCO Health Care
- Exchange
- JXG Nasdaq
- ONCO Nasdaq
- Market Cap
- JXG 5.2M
- ONCO 5.8M
- IPO Year
- JXG N/A
- ONCO 2022
- Fundamental
- Price
- JXG $2.39
- ONCO $0.40
- Analyst Decision
- JXG
- ONCO
- Analyst Count
- JXG 0
- ONCO 0
- Target Price
- JXG N/A
- ONCO N/A
- AVG Volume (30 Days)
- JXG 34.7K
- ONCO 9.9M
- Earning Date
- JXG 12-06-2024
- ONCO 04-10-2025
- Dividend Yield
- JXG N/A
- ONCO N/A
- EPS Growth
- JXG N/A
- ONCO N/A
- EPS
- JXG 2.20
- ONCO N/A
- Revenue
- JXG $38,490,872.00
- ONCO $1,870,605.00
- Revenue This Year
- JXG N/A
- ONCO N/A
- Revenue Next Year
- JXG N/A
- ONCO N/A
- P/E Ratio
- JXG $1.09
- ONCO N/A
- Revenue Growth
- JXG N/A
- ONCO N/A
- 52 Week Low
- JXG $0.75
- ONCO $0.32
- 52 Week High
- JXG $4.92
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- JXG N/A
- ONCO 33.18
- Support Level
- JXG N/A
- ONCO $0.58
- Resistance Level
- JXG N/A
- ONCO $0.70
- Average True Range (ATR)
- JXG 0.00
- ONCO 0.06
- MACD
- JXG 0.00
- ONCO -0.01
- Stochastic Oscillator
- JXG 0.00
- ONCO 0.00
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc, formerly JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.